Error parsing response

9 months ago1 min read

Error occurred while parsing the model response.

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Clinical Trials

Related research and studies

Highlighted Clinical Trials

KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment

NCT03662126RecruitingPhase 2

Kartos Therapeutics, Inc.

Posted 1/15/2019

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

NCT03914625Active, Not RecruitingPhase 3

National Cancer Institute (NCI)

Posted 7/3/2019

A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma

NCT02316106CompletedPhase 2

Janssen Research & Development, LLC

Posted 5/20/2015

Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)

NCT03483103CompletedPhase 2

Juno Therapeutics, a Subsidiary of Celgene

Posted 7/27/2018

Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)

NCT04603495Active, Not RecruitingPhase 3

Constellation Pharmaceuticals

Posted 4/9/2021

A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia, Who do Not Have a β0/β0 Genotype

NCT02906202CompletedPhase 3

bluebird bio

Posted 8/8/2016

A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia

NCT03207009CompletedPhase 3

bluebird bio

Posted 6/8/2017

A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.

NCT04680052Active, Not RecruitingPhase 3

Incyte Corporation

Posted 4/15/2021

Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission

NCT03267433Active, Not RecruitingPhase 3

ECOG-ACRIN Cancer Research Group

Posted 11/27/2017

A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas

NCT03575351CompletedPhase 3

Celgene

Posted 10/23/2018

Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome

NCT04623541RecruitingPhase 1

Genmab

Posted 11/25/2020

A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL

NCT03336333Active, Not RecruitingPhase 3

BeiGene

Posted 10/31/2017

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)

NCT05406401Active, Not RecruitingPhase 2

Merck Sharp & Dohme LLC

Posted 7/14/2022

Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL

NCT03836261Active, Not RecruitingPhase 3

Acerta Pharma BV

Posted 2/25/2019

Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)

NCT04146051Active, Not RecruitingPhase 2

Cartesian Therapeutics

Posted 12/4/2019

Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis

NCT04562389RecruitingPhase 3

Karyopharm Therapeutics Inc

Posted 3/11/2021

A Study Evaluating the Safety and Efficacy of LentiGlobin BB305 Drug Product in β-Thalassemia Major (Also Referred to as Transfusion-dependent β-Thalassemia [TDT]) and Sickle Cell Disease

NCT02151526CompletedPhase 1

bluebird bio

Posted 6/7/2013

A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

NCT03301220Active, Not RecruitingPhase 3

Janssen Research & Development, LLC

Posted 11/7/2017

A Phase 1/2 Study of AURN001 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction (ABA-1)

NCT06041256Active, Not RecruitingPhase 1

Aurion Biotech

Posted 10/18/2023

A Study Evaluating the Safety and Efficacy of the LentiGlobin BB305 Drug Product in β-Thalassemia Major Participants

NCT01745120CompletedPhase 1

bluebird bio

Posted 8/1/2013

Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma

NCT03568461CompletedPhase 2

Novartis Pharmaceuticals

Posted 11/12/2018

Long-term Follow-up of Subjects With Transfusion-Dependent β-Thalassemia (TDT) Treated With Ex Vivo Gene Therapy

NCT02633943Active, Not Recruiting

bluebird bio

Posted 1/1/2014

A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma

NCT04181827Active, Not RecruitingPhase 3

Janssen Research & Development, LLC

Posted 6/12/2020

A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

NCT03652064Active, Not RecruitingPhase 3

Janssen Research & Development, LLC

Posted 11/6/2018

Sources

Press Release: ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients

br.advfn.comDec 12, 2024

Subcutaneous Daratumumab Significantly Delays Progression in Smoldering Myeloma

targetedonc.comDec 9, 2024

Promising Advances in Hematology: Key Findings From ASH 2024

targetedonc.comDec 17, 2024

DARZALEX® (daratumumab) subcutaneous formulation shows 51 - GlobeNewswire

globenewswire.comDec 8, 2024

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) shows 51 percent reduction ...

morningstar.comDec 8, 2024

An Assortment of Journal Abstracts to Enhance Oncology Care

journals.lww.comJan 28, 2025

ICYMI: Highlights From ASH 2024 - American Journal of Managed Care

ajmc.comDec 29, 2024

EU Approves Sanofi's (SNY) Sarclisa for Newly Diagnosed Multiple ...

finviz.comAug 2, 2025

J&J drug helps delay multiple myeloma in high-risk patients - Pharmacy.biz

pharmacy.bizDec 19, 2024

Daratumumab Reduces Risk of Progression in High-Risk Smoldering Multiple Myeloma Patients

insideprecisionmedicine.comDec 12, 2024

ASH24: Darzalex in smoldering myeloma, Merck's ADC data and Novo's sickle cell drug

biopharmadive.comDec 9, 2024

Daratumumab treatment shows promise for high-risk smoldering multiple myeloma in phase 3 trial

news-medical.netDec 10, 2024

Sanofi's Sarclisa Expands into First-Line Multiple Myeloma Therapy: A Strategic Win with ...

ainvest.comJul 26, 2025

From Blinatumomab to Venetoclax: Highlights From the 66th American Society ... - Pharmacy Times

pharmacytimes.comJan 19, 2025

Sanofi gets first OK for isatuximab for myeloma, challenging J&J's Darzalex

pharmaphorum.comApr 29, 2025

ASH: Sanofi’s Sarclisa carves out a multiple myeloma niche

pharmaphorum.comJun 16, 2025

Sanofi's Sarclisa: A Game-Changer in Multiple Myeloma Therapy and a Strategic Buy for ...

ainvest.comJul 25, 2025

Daratumumab Reduces Risk of Progression in High-Risk Smoldering Multiple Myeloma Patients

insideprecisionmedicine.comDec 13, 2024

J&J's DARZALEX FASPRO Shows Breakthrough 51% Risk Reduction in Multiple Myeloma Trial

stocktitan.netDec 8, 2024

Kiadis Pharma and Sanofi to unlock power of natural killer cells in multiple myeloma

pharmaphorum.comMay 5, 2025

Sanofi's Sarclisa Expands EU Approval in Multiple Myeloma: A Strategic Step in Frontline ...

ainvest.comJul 25, 2025

ASH 2024 Recap: Movement in Multiple Myeloma, Cell Therapy, Sickle Cell Disease & More

medcitynews.comDec 12, 2024

Sanofi Advances Multiple Myeloma Treatments with EU Approval and US Orphan Drug Designation

tipranks.comJul 31, 2025

PFS, OS Significantly Improved by Daratumumab for Smoldering Multiple Myeloma

cancernetwork.comDec 8, 2024

ASH 2024: Pharmacists Play Key Role in Incorporating Venetoclax, Blinatumomab for ...

pharmacytimes.comDec 7, 2024

Sanofi's Sarclisa gets one up on rival Darzalex in myeloma

pharmaphorum.comJun 18, 2025

Daratumumab Demonstrates Significant Benefit in High-Risk Smoldering Myeloma - Pharmacy Times

pharmacytimes.comDec 8, 2024

ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients

pharmiweb.comDec 10, 2024

Sarclisa's EU Approval Milestone Positions Sanofi as Oncology ...

ainvest.comJun 23, 2025

Sanofi builds case for Sarclisa, challenging J&J's Darzalex

pharmaphorum.comJun 18, 2025

FDA sets date for Sarclisa in first-line multiple myeloma

pharmaphorum.comJun 30, 2025

Experts Debate AQUILA Trial Findings in Smoldering Multiple Myeloma | MedPage Today

medpagetoday.comDec 16, 2024

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) shows 51 percent reduction ...

prnewswire.comDec 8, 2024

Sanofi's multiple myeloma drug approved in EU

pharmaphorum.comMay 2, 2025

Daratumumab Continues to Show Activity in Smoldering Multiple Myeloma - Cancer Network

cancernetwork.comMar 23, 2025

Press Release: ASH: Sarclisa combinations demonstrated significant benefits in newly ...

sanofi.comDec 9, 2024

Daratumumab Monotherapy Shows Survival Benefit in Smoldering ...

oncnursingnews.comDec 9, 2024

Data Roundup: December 2024 Features Updates for Cilta-Cel in Multiple Myeloma, mRNA ...

cgtlive.comJan 6, 2025

Blackstone funds new trials of Sanofi's Sarclisa in myeloma

pharmaphorum.comMar 14, 2022

AI-Powered Research

Premium Access

Stay Updated with Our Daily Newsletter

Clinical Trials

Highlighted Clinical Trials

KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma

Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)

Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)

A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia, Who do Not Have a β0/β0 Genotype

A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia

A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.

Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission

A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas

Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome

A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)

Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL

Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)

Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis

A Study Evaluating the Safety and Efficacy of LentiGlobin BB305 Drug Product in β-Thalassemia Major (Also Referred to as Transfusion-dependent β-Thalassemia [TDT]) and Sickle Cell Disease

A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

A Phase 1/2 Study of AURN001 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction (ABA-1)

A Study Evaluating the Safety and Efficacy of the LentiGlobin BB305 Drug Product in β-Thalassemia Major Participants

Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma

Long-term Follow-up of Subjects With Transfusion-Dependent β-Thalassemia (TDT) Treated With Ex Vivo Gene Therapy

A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma

A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

Related News

Sources

Royalty Pharma Acquires $950 Million IMDELLTRA Royalty Rights from BeOne Medicines

GSK Launches First PD-1 Immunotherapy and PARP Inhibitor for Gynecological Cancers in India

BioArctic and Novartis Partner on BrainTransporter Technology for Neurodegeneration Treatment Development

Catalyst Pharmaceuticals Secures Patent Protection for FIRDAPSE Until 2035 Through Lupin Settlement

Roche Breaks Ground on $700M North Carolina Manufacturing Facility for Next-Generation Obesity Treatments

VYVGART Achieves Primary Endpoint in Phase 3 Trial for AChR-Ab Seronegative Myasthenia Gravis

Curanex Pharmaceuticals Raises $15 Million in IPO to Advance Ulcerative Colitis Treatment

FDA Expands Repatha Indication to Include Adults at High Risk for Cardiovascular Events Without Prior Disease Diagnosis

Virax Biolabs Partners with Emory University for Long COVID Diagnostic Study Using T Cell Technology

MannKind Acquires scPharmaceuticals for Up to $360M to Expand Cardiorenal Portfolio

MedPath

Product

Company

Legal